Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the activity of oral AB1010, administered at two
dose levels during 3 years to patients with primary or secondary progressive multiple
sclerosis.